Enter your Email address:
Wolters Kluwer Health may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
You currently have no recent searches
Navani, Neal MA, MRCP; Spiro, Stephen G. MD, FRCP; Janes, Sam M. MRCP, MSc, PhD
Centre for Respiratory Research, University College London, United Kingdom, email@example.com
Disclosure: The authors declare no conflicts of interest.
The mediastinal staging of non-small cell lung cancer is an important process that distinguishes operable from inoperable candidates. In their retrospective study, Rintoul et al.1 report the utility of endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) for the diagnosis of positron emission tomography (PET) positive mediastinal and hilar lymph nodes. They demonstrate a sensitivity of EBUS-TBNA of 91% when reference pathology was available.
The high false-positive rate of PET for the detection of mediastinal metastases demands that PET-positive mediastinal nodes should be invasively sampled and proven to contain metastatic disease before radical treatment is precluded. However, in addition to a high false-positive rate, it is increasingly recognized that PET is associated with a significant false-negative rate. The pooled sensitivity of PET for detecting mediastinal metastases from a meta-analysis was 0.74 (95% CI 0.69-0.79) and therefore PET scanning fails to detect over a quarter of mediastinal metastases in non-small cell lung cancer.2 This is reflected by current guidelines which suggest that all mediastinal lymph nodes ≥1 cm should be sampled preoperatively, regardless of fluorodeoxyglucose-avidity.3 Emerging data also suggests that malignancy can be detected in PET negative mediastinal nodes that are less than 1 cm in short axis.4 Therefore, a strategy where PET positive mediastinal lymph nodes alone are sampled should not be advocated.
The value of PET lies in its ability to detect radiographically occult extrathoracic metastases5 and should be applied preoperatively in all cases. However, EBUS-TBNA has a higher sensitivity for the detection of mediastinal metastases than PET. Therefore restricting the application of EBUS-TBNA to only PET positive mediastinal nodes would miss mediastinal metastases preoperatively and result in futile thoracotomies.
Neal Navani, MA, MRCP
Stephen G. Spiro, MD, FRCP
Sam M. Janes, MRCP, MSc, PhD
Centre for Respiratory Research
University College London
© 2009International Association for the Study of Lung Cancer
Colleague's E-mail is Invalid
Your Name: (optional)
Separate multiple e-mails with a (;).
Thought you might appreciate this item(s) I saw at Journal of Thoracic Oncology.
Send a copy to your email
Your message has been successfully sent to your colleague.
Some error has occurred while processing your request. Please try after some time.
An Existing Folder
A New Folder
The item(s) has been successfully added to "".
Login with your LWW Journals username and password.
Username or Email:
Enter and submit the email address you registered with. An email with instructions to reset your password will be sent to that address.
Link to reset your password has been sent to specified email address.
What does "Remember me" mean?
By checking this box, you'll stay logged in until you logout. You'll get easier access to your articles, collections,
media, and all your other content, even if you close your browser or shut down your
To protect your most sensitive data and activities (like changing your password),
we'll ask you to re-enter your password when you access these services.
What if I'm on a computer that I share with others?
If you're using a public computer or you share this computer with others, we recommend
that you uncheck the "Remember me" box.
Save my selection
Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.
For additional oncology content, visit LWW Oncology Journals on Facebook.